Quarterly Report (10-q)

Date : 08/14/2019 @ 5:13PM
Source : Edgar (US Regulatory)
Stock : Alr Technologies, Inc. (PC) (ALRT)
Quote : 0.0382  -0.0001 (-0.26%) @ 8:59PM

Quarterly Report (10-q)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019
    
  OR
    
[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-30414

 

ALR TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

NEVADA

(State or other jurisdiction of incorporation or organization)

 

88-0225807

(I.R.S. Employer Identification No.)

 

7400 Beaufont Springs Drive Suite 300

Richmond, VA 23225

(Address of principal executive offices, including zip code.)

 

(804) 554-3500

(Telephone number, including area code)

 

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES [ X ] NO [ ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (SS 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES [X] NO [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

  Large Accelerated Filer [   ]   Accelerated Filer [   ]
  Non-accelerated Filer [   ]   Smaller Reporting Company [X]
  (Do not check if smaller reporting company)      

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES [ ] NO [ X ]

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 268,777,909 as of August 14, 2019.

 

 

 
 

ALR TECHNOLOGIES INC.

TABLE OF CONTENTS

 

 

PART I. FINANCIAL INFORMATION  
    
Item 1. Financial Statements.  
  Condensed Balance Sheets (unaudited) 4
  Condensed Statements of Operations (unaudited) 5
  Condensed Statements of Cash Flows (unaudited) 6
  Notes to Condensed Financial Statements (unaudited) 7
      
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 21
      
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 35
      
Item 4. Controls and Procedures. 35
      
      
  PART II. OTHER INFORMATION  
      
Item 1. Legal Proceedings. 35
      
Item 1A. Risk Factors. 35
      
Item 3. Defaults Upon Senior Securities. 35
      
Item 5. Other Information. 35
      
Item 6. Exhibits. 36
      
Signatures 37

 

 

 

 
 

PART I. FINANCIAL INFORMATION

 

ITEM 1. CONDENSED FINANCIAL STATEMENTS.

 

 

 

 

ALR TECHNOLOGIES INC.

Condensed Financial Statements

June 30, 2019 and 2018

(unaudited)

 

Index Page
   
Condensed Balance Sheets 4
   
Condensed Statements of Operations 5
   
Condensed Statements of Cash Flows 6
   
Notes to Condensed Financial Statements 7 – 20

  

 

 
 

ALR TECHNOLOGIES INC.

Condensed Balance Sheets

($ United States)

 

 

         
    June 30,
2019
  December 31, 2018
    (unaudited)    
         
Assets                
Current assets:                
Cash   $ 3,723     $ 3,378  
Total assets   $ 3,723     $ 3,378  
                 
Liabilities and Stockholders' Deficit                
Current liabilities:                
Accounts payable and accrued liabilities   $ 1,047,775     $ 1,014,268  
Promissory notes payable to related parties     2,891,966       2,891,966  
Promissory notes payable to unrelated parties     2,394,353       2,394,353  
Interest payable     5,100,561       4,836,127  
Lines of credit from related parties     18,230,614       17,261,650  
Total liabilities     29,665,269       28,398,364  
                 
Stockholders' Deficit                
Preferred stock:                
Authorized: 500,000,000 (December 31, 2018 - 500,000,000) shares of preferred stock with a par value of $0.001 per share                
Shares issued and outstanding: Nil (December 31, 2018 - Nil) shares of preferred stock were issued and outstanding     —         —    
Common stock:                
Authorized: 10,000,000,000 (December 31, 2018 - 10,000,000,000) shares of common stock with a par value of $0.001 per share                
Shares issued and outstanding: 268,777,909 shares of common stock (December 31, 2018 - 242,777,909 shares of common stock)     268,777       242,777  
Additional paid-in capital     53,444,532       50,012,445  
Accumulated deficit     (83,374,855 )     (78,650,208 )
Stockholders’ deficit     (29,661,546 )     (28,394,986 )
Total liabilities and stockholders’ deficit   $ 3,723     $ 3,378  

 

 

See accompanying notes to the condensed financial statements.

  4  

 

ALR TECHNOLOGIES INC.

Condensed Statements of Operations

($ United States)

(Unaudited)

 

 

    Three months ended   Six months ended
    June 30,   June 30,
    2019   2018   2019   2018
                 
Expenses                                
General, selling and administration   $ 641,942     $ 95,160     $ 986,683     $ 1,155,747  
Product development costs     1,162,879       55,164       1,217,901       295,798  
Professional fees     208,957       199,260       437,234       422,135  
Loss from operations     2,013,778       349,584       2,641,818       1,873,680  
                                 
Other Expense                                
Interest     1,586,936       482,522       2,082,829       959,263  
Total other expense     1,586,936       482,522       2,082,829       959,263  
Net loss   $ (3,600,714 )   $ (832,106 )   $ (4,724,647 )   $ (2,832,943 )
Loss per share - basic and diluted   $ (0.01 )   $ (0.00 )   $ (0.02 )   $ (0.01 )
                                 
Weighted average shares outstanding -
basic and diluted
    245,955,687       242,777,909       244,366,798       242,777,909  

 

 

 

See accompanying notes to the condensed financial statements.

  5  

 

ALR TECHNOLOGIES INC.

Condensed Statements of Cash Flows

($ United States)

(Unaudited)

 

 

     
    Six Months Ended
    June 30,
    2019   2018
         
OPERATING ACTIVITIES                
Net loss   $ (4,724,647 )   $ (2,832,943 )
Stock-based compensation-interest     1,085,371       —    
Stock-based compensation-product development costs     1,048,318       185,404  
Stock-based compensation-professional fees     392,677       401,151  
Stock-based compensation-selling, general and administration     805,865       977,576  
Non-cash imputed interest expenses     60,856       60,322  
Accrued interest on line of credit     672,145       634,506  
Changes in operating assets and liabilities:                
Increase (decrease) in accounts payable and accrued liabilities     48,507       (23,770 )
Increase in interest payable     264,434       264,435  
                 
Net cash used in operating activities     (346,474 )     (333,319 )
                 
FINANCING ACTIVITIES                
Proceeds from borrowings on line of credit     346,819       330,338  
                 
Net cash provided by financing activities     346,819       330,338  
                 
Increase (decrease) in cash     345       (2,981 )
Cash, beginning of period     3,378       3,111  
                 
Cash, end of period   $ 3,723     $ 130  

 

 

See accompanying notes to the condensed financial statements.

  6  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

1.       Basis of Presentation, Nature of Operations and Going Concern

 

ALR Technologies Inc. (the “Company”) was incorporated under the laws of the state of Nevada on March 24, 1987. The Company has developed a compliance monitoring system that will allow for health care professionals to remotely monitor patient health conditions and provide patient health management. On October 17, 2011 the Company announced that it had received Section 510(k) clearance from the United States Food and Drug Administration for its Diabetes Management System. The Company is currently seeking pilot programs to deploy its product.

 

These condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) in US dollars and on a going concern basis, which presumes the realization of assets and the discharge of liabilities and commitments in the normal course of operations for the foreseeable future. Several adverse conditions cast substantial doubt on the validity of this assumption. The Company has incurred significant losses over the six-month periods ended June 30, 2019 and 2018 of $4,724,647 and $2,832,943. As of June 30, 2019, the Company is unable to self-finance its operations, has a working capital deficit of $29,661,546 (December 31, 2018 - $28,394,986), accumulated deficit of $83,374,855 (December 31, 2018 - $78,650,208), limited resources, no source of operating cash flow and no assurance that sufficient funding will be available to conduct continued product development activities. If the Company is able to finance its required product development activities, there is no assurance the Company’s current projects will be commercially viable or profitable. The Company has debts comprised of accounts payable, interest payable, lines of credit and promissory notes payable totaling $29,665,269 currently due, due on demand or considered delinquent. There is no assurance that the Company will not face additional legal action from creditors regarding the above debts. Any one or a combination of these above conditions could result in the failure of the business and cause the Company to cease operations.

 

The Company’s ability to continue as a going concern is dependent upon the continued financial support of its creditors and its ability to obtain financing to fund working capital and overhead requirements, fund the development of the Company’s product line and, ultimately, the Company’s ability to achieve profitable operations and repay overdue obligations. The Company has obtained short-term financing from its chairman’s family through lines of credit facilities with available borrowing in the principal amount up to $10,500,000 (as of June 30, 2019 the total principal balance outstanding was $11,371,054) (note 5). During 2019, the Company has continued to receive financing from the Chairman in excess of the borrowing limit of the line of credit it has available. The amounts received by the Company from the Chairman have been borrowed under the same terms as the line of credit. The Company and the Chairman have not entered into a new agreement for the amount of borrowing available.

 

The resolution of whether the Company is able to continue as a going concern is dependent upon the realization of management’s plans. The Company plans to raise needed capital through the exercise of share options, increase to existing debt facilities or the acquisition of new debt facilities, and by future common share private placements. There can be no assurance that the Company will be able to raise any additional debt or equity capital from the sources described above, or that the lenders in the line of credit arrangements will maintain the availability of borrowing from the line. If management is unsuccessful in obtaining short-term financing or achieving long-term profitable operations, the Company will be required to cease operations.

 

 

 

  7  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

1.       Basis of Presentation, Nature of Operations and Going Concern (continued)

 

All of the Company’s debt is either due on demand or is in default, while continuing to accrue interest at its stated rate. The Company will seek to obtain creditors’ consents to delay repayment of the outstanding promissory notes payable and related interest thereto, until it is able to replace this financing with funds generated by operations, recapitalization with replacement debt or from equity financings through private placements. While some of the Company’s creditors have agreed to extend repayment deadlines in the past, there is no assurance that they will continue to do so in the future. In the past, creditors have successfully commenced legal action against the Company to recover debts outstanding. In those instances, the Company was able to obtain financing from related parties to cover the verdict or settlement; however, there is no assurance that the Company would be able to obtain the same financing in the future. If the Company is unsuccessful in obtaining financing to cover any potential verdicts or settlements, the Company will be required to cease operations.

 

The Company’s activities will necessitate significant uses of working capital beyond 2019. Additionally, the Company’s capital requirements will depend on many factors, including the success of the Company’s continued product development and distribution efforts. The Company plans to continue financing its operations with the lines of credit it has available and future debt arrangements it obtains.

 

While the Company strongly believes that its capital resources will be sufficient in the near term, there is no assurance that the Company’s activities will generate sufficient revenues to sustain its operations without additional capital or if additional capital is needed, that such funds, if available, will be obtainable on terms satisfactory to the Company.

 

2.       Significant Accounting Policies

 

The unaudited condensed financial statements as of June 30, 2019 and for the period then ended have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading.

 

In the opinion of management, all adjustments necessary to present fairly the financial position as of June 30, 2019 and December 31, 2018 and the results of operations and cash flows as of June 30, 2019 and 2018, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments.

 

These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

 

The results of operations for the six-month period ended June 30, 2019 are not necessarily indicative of the results to be expected for the full year.

 

  8  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

3.        Accounts Payable and Accrued Liabilities

 

A summary of the accounts payable and accrued liabilities is as follows:

 

 

   

June 30,

2019 

  December 31, 2018 
         
Accounts payable   $ 765,289     $ 774,830  
Accrued liabilities     282,486       239,438  
                 
    $ 1,047,775     $ 1,014,268  

 

4.       Promissory Notes and Interest Payable

 

a)       Promissory notes payable to related parties:

 

A summary of the promissory notes payable to related parties is as follows:

 

 

Promissory Notes Payable to Related Parties

June 30,

2019

December 31,

2018

 
         
Promissory notes payable to relatives of directors collateralized by a general security agreement on all the assets of the Company, due on demand:        
             
  i. Interest at 1% per month $ 580,619 $ 580,619
             
  ii. Interest at 1.25% per month   51,347   51,347
             
  iii. Interest at the U.S. bank prime rate plus 1%   100,000   100,000
             
  iv. Interest at 0.5% per month   695,000   695,000
         
Promissory notes payable, unsecured, to relatives of a director, bearing interest at 1% per month, due on demand   1,465,000   1,465,000
Total Promissory Notes Payable to Related Parties $ 2,891,966 $ 2,891,966

 

 

 

  9  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

4.       Promissory Notes and Interest Payable (continued)

 

b)       Promissory notes payable to unrelated parties

 

A summary of the promissory notes payable to unrelated parties is as follows:

 

Promissory Notes Payable to Unrelated Parties June 30, December 31,
  2019 2018
         
Unsecured promissory notes payable to unrelated lenders:        
             
  i. Interest at 1% per month, repayable on March 31, 2009, due on demand $ 450,000 $ 450,000
             
  ii. Interest at 1% per month, with $50,000 repayable on December 31, 2004, $75,000 repayable on August 18, 2007, $75,000 repayable on November 19, 2007 and the balance due on demand. All are due on demand, accruing interest at the same rate   887,456   887,456
             
  iii. Interest at 0.625% per month, with $50,000 repayable on October 5, 2004, $40,000 repayable on December 31, 2004, and $60,000 repayable on July 28, 2006, all due on demand   150,000   150,000
             
  iv. Non-interest-bearing, repayable on July 17, 2005, due on demand   270,912   270,912
             
  v. Interest at 0.667% per month, repayable at $25,000 per month beginning October 2009, none repaid to date   310,985   310,985
             
  vi. Interest at 0.667% per month, with $125,000 due January 15, 2011   125,000   125,000
           
Promissory notes payable, secured by a guarantee from the Chief Executive Officer, bearing interest at 1% per month   200,000   200,000
Total Promissory Notes Payable to Unrelated Parties $ 2,394,353 $ 2,394,353

 

 

 

c)       Interest payable

 

A summary of the interest payable activity is as follows:

 

    Interest
Payable
     
Balance, December 31, 2017   $ 4,307,256  
Interest incurred on promissory notes payable     528,871  
         
Balance, December 31, 2018     4,836,127  
Interest incurred on promissory notes payable     264,434  
         
Balance, June 30, 2019   $ 5,100,561  

 

  10  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

4.       Promissory Notes and Interest Payable (continued)

 

c)       Interest payable (continued)

 

       
    June 30,   December 31,
    2019   2018
         
Related parties (relatives of the Chairman)   $ 2,726,716     $ 2,554,655  
Non-related parties     2,373,845       2,281,472  
                 
    $ 5,100,561     $ 4,836,127  

  

Historically, all interest payable incurred is from interest incurred at the stated rate of promissory notes issued by the Company. The payment terms, security and any interest payable are based on the underlying promissory notes payable that the Company has outstanding.

 

d)       Interest expense

 

During the six months ended June 30, 2019, the Company incurred interest expense of $2,082,829 (2018 - $959,263) substantially as follows:

 

- $1,085,371 (2018 - $nil) incurred related to the modification of the option held by creditors of the Company to acquire shares of common stock which were granted as consideration for providing financing to the Company;
- $672,145 (2018 - $634,506) incurred on lines of credit payable;
- $264,434 (2018 - $264,435) incurred on promissory notes payables as shown in note 4(b), and
- $60,856 (2018 - $60,322) incurred from the calculation of imputed interest on accounts payable outstanding for longer than one year, advances payable and promissory notes payable, which had no stated interest rate.

 

 

  11  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

5.        Lines of Credit

 

As of June 30, 2019, the Company had two lines of credit as follows:

 

Creditor

Interest

Rate

Borrowing

Limit

Repayment

Terms

Amount

Outstanding

Accrued

Interest

Total Security Purpose
Chairman and CEO

1% per

Month

$ 8,500,000

Due on

Demand

$ 9,371,054 $5,003,175 $14,374,229

General

Security

over Assets

General

Corporate Requirements

Wife of Chairman

1% per

Month

2,000,000

Due on

Demand

2,000,000 1,856,385 3,856,385

General

Security

over Assets

General

Corporate Requirements

Total   $10,500,000   $11,371,054 $6,859,560 $18,230,614    

 

The Chairman has continued to provide financing to the Company in excess of the line of credit borrowing limit available under the same terms as the existing line of credit facility.

 

As of December 31, 2018, the Company had two lines of credit as follows:

 

Creditor Interest Rate Borrowing Limit Repayment Terms Principal Borrowed Accrued Interest

Total

Outstanding

Security Purpose
Chairman and CEO 1% per Month $ 8,500,000 Due on Demand $ 9,024,235 $ 4,501,030 $13,525,265 General Security over Assets General Corporate Requirements
Wife of Chairman 1% per Month 2,000,000 Due on Demand 2,000,000 1,736,385 3,736,385 General Security over Assets General Corporate Requirements
Total   $10,500,000   $11,024,235 $6,237,415 $17,261,650    

 

6.       Capital Stock

 

a) Authorized capital stock

 

i. Common Stock

 

10,000,000,000 shares of common stock with a par value of $0.001 per share.

 

ii. Preferred Stock

 

500,000,000 shares of preferred stock with a par value of $0.001 per share.

 

  12  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

6.         Capital Stock (continued)

 

b)       Issued capital stock

 

During the period ended June 30, 2019:

 

On June 19, 2019, the Company issued 26,000,000 shares of common stock of the Company to two individuals for the exercise of stock options as follows:

· 25,000,000 shares at an exercise price of $0.002 per share for a purchase price of $50,000, as consideration, the Company retired accrued interest owing to the Chairman on his line of credit totaling $50,000; and
· 1,000,000 shares at an exercise price of $0.015 per share for a purchase price of $15,000, as consideration, the Company retired accounts payable totaling $15,000.

 

During the year ended December 31, 2018:

 

There were no capital stock issuances for the year ended December 31, 2018.

 

7.        Additional Paid-in Capital

 

Stock options

 

A summary of stock option activity is as follows:

 

  Six Months Ended Year Ended
  June 30, 2019 December 31, 2018
  Number of   Weighted Average Number of   Weighted Average
  Options   Exercise Price Options   Exercise Price
Outstanding, beginning of period 5,014,851,500 $ 0.002 4,963,851,500 $ 0.002
Granted 112,550,000 $ 0.040 52,500,000 $ 0.015
Exercised (26,000,000) $ 0.003 - $ -
Cancelled (4,000,000) $ 0.015 (1,500,000) $ 0.015
Outstanding, end of period 5,097,401,500 $ 0.003 5,014,851,500 $ 0.002
              
Exercisable, end of period 5,021,801,500 $ 0.003 4,987,851,500 $ 0.002
               

 

 

  13  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

7.        Additional Paid-in Capital (continued)

 

Stock options (continued)

 

During the period ended June 30, 2019:

 

On February 4, 2019, the Company granted a consultant options to acquire a total of 2,500,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years. The fair value of the options granted totaled $99,723.

 

On March 15, 2019, the Company granted options to acquire 9,150,000 shares of common stock of the Company at a price of $0.035 per share. The options to acquire 2,500,000 shares of common stock was granted to one consultant and the option to acquire 6,650,000 shares of common stock was granted to one director. The fair value of the options granted totaled $364,058.

 

On April 12, 2019, the Company modified options to acquire 564,350,200 shares of common stock of the Company by extending the expiry date to April 12, 2024. The options modified had expiration dates ranging from April 19, 2019 to May 29, 2020 immediately prior to the modification. The fair value related to the extension of the life of the options totaled $1,150,060.

 

On May 6, 2019, the Company granted options to acquire 13,000,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to three directors of the Company. The fair value of the options granted totaled $467,845.

 

On May 17, 2019, the Company granted options to acquire 27,900,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to twelve consultants and one employee of the Company. The fair value of the options granted totaled $1,059,856.

 

On May 31, 2019, the Company granted options to acquire 10,000,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to one consultant. The option to acquire 10,000,000 shares will vest based on achievements of performance milestones. The fair value of the options granted totaling $399,722 was not recorded, as it cannot be determined that it is more likely than not that the performance conditions will be met.

 

On June 12, 2019, the Company granted options to acquire 40,000,000 shares of common stock of the Company at a price of $0.05 per share for a term of five years to three sales agents. The option to acquire 40,000,000 shares will vest based on achievements of performance milestones. The fair value of the options granted totaling $1,595,316 was not recorded, as it cannot be determined that it is more likely than not that the performance conditions will be met.

 

On June 17, 2019, the Company granted options to acquire 10,000,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to one advisor and one sales agent. The fair value of the options granted totaled $379,730, of which $189,865 related to vested options was recorded as compensation expense and $189,865 related to options with performance vesting conditions was not recorded, as it cannot be determined that it is more likely than not that the performance conditions will be met .

 

  14  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

7.        Additional Paid-in Capital (continued)

 

Stock options (continued)

 

On June 24, 2019, options granted on January 31, 2018 to acquire 24,000,000 shares of common stock at a price of $0.015 for a term of five years which were subject to vest based on the achievement of certain performance milestones was modified as follows:

 

· the option to acquire 4,000,000 shares of common stock was cancelled; and
· the performance conditions were modified.

 

No compensation expense was reversed related to the cancellation of the unvested options as no compensation expense related to these options had been previously recorded. No compensation expense related to the modification of the options was recorded, as the change in vesting conditions did not make it more likely than not that the performance conditions will be met.

 

The Company recorded a further $824 in compensation expense related to vesting of stock options granted in previous years.

 

During the year ended December 31, 2018:

 

On January 31, 2018, the Company granted to nine consultants and advisors the option to acquire a total of 47,000,000 shares of common stock of the Company at a price of $0.015 per share for a term of five years and one advisor the option to acquire 200,000 shares of common stock of the Company at a price of $0.03 per share until April 18, 2019. Options to acquire 24,000,000 shares of common stock will vest based on achievements of performance milestones by one consulting group. The fair value of the options granted totaled $2,722,605, of which $1,338,207 related to vested options was recorded as compensation expense and $1,384,398 related to options with performance vesting conditions was not recorded, as it cannot be determined that it is more likely than not that the performance conditions will be met.

 

On June 13, 2018, the Company granted a consultant the option to acquire a total of 5,000,000 shares of common stock of the Company at a price of $0.015 per share for a term of five years. The fair value of the options granted totaled $189,968.

 

On October 1, 2018, the Company granted a consultant the option to acquire a total of 300,000 shares of common stock of the Company at a price of $0.05 per share for a term of five years. The fair value of the options granted totaled $15,926.

 

The Company recorded a further $37,242 in compensation expense related to vesting of stock options granted in previous years.

 

  15  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

7.        Additional Paid-in Capital (continued)

 

Stock options (continued)

 

Options Outstanding:

 

The options outstanding at June 30, 2019 and December 31, 2018 were as follows:

 

    June 30, 2019   December 31, 2018
Expiry Date   Options Exercise Price Intrinsic Value   Options Exercise Price Intrinsic Value
                         
April 18, 2019   - $ - $ -   200,000 $ 0.030 $ 0.005
May 21, 2019   - $ - $ -   500,000 $ 0.015 $ 0.020
July 25, 2019   - $ - $ -   1,000,000 $ 0.015 $ 0.020
August 1, 2019   - $ - $ -   1,250,000 $ 0.015 $ 0.020
January 30, 2020   - $ - $ -   2,400,000 $ 0.015 $ 0.020
May 29, 2020   - $ - $ -   560,000,200 $ 0.002 $ 0.033
July 1, 2021   4,365,001,300 $ 0.002 $ 0.039   4,390,001,300 $ 0.002 $ 0.033
November 27, 2022   7,200,000 $ 0.015 $ 0.026   7,200,000 $ 0.015 $ 0.020
January 31, 2023   43,000,000 $ 0.015 $ 0.026   47,000,000 $ 0.015 $ 0.020
June 13, 2023   5,000,000 $ 0.015 $ 0.026   5,000,000 $ 0.015 $ 0.020
October 1, 2023   300,000 $ 0.050 $ -   300,000 $ 0.050 $ -
February 3, 2024   2,500,000 $ 0.035 $ 0.006   - $ - $ -
March 14, 2024   9,150,000 $ 0.035 $ 0.006   - $ - $ -
April 12, 2024   560,000,200 $ 0.002 $ 0.039   - $ - $ -
April 12, 2024   4,150,000 $ 0.015 $ 0.026   - $ - $ -
April 12, 2024   200,000 $ 0.030 $ 0.006   - $ - $ -
May 6, 2024   13,000,000 $ 0.035 $ 0.006   - $ - $ -
May 17, 2024   27,900,000 $ 0.035 $ 0.006   - $ - $ -
May 17, 2024   40,000,000 $ 0.050 $ -   - $ - $ -
May 31, 2024   10,000,000 $ 0.035 $ 0.006   - $ - $ -
June 17, 2024   10,000,000 $ 0.035 $ 0.006   - $ - $ -
Total   5,097,401,500 $ 0.003 $ 0.039   5,014,851,500 $ 0.002 $ 0.033

Weighted Average Remaining

Contractual Life

  3.14           2.40    

 

The expense incurred related to stock options was allocated as follows:

 

    Three Months
Ended
June 30, 2019
  Three Months
Ended
June 30, 2018
  Six Months
Ended
June 30, 2019
  Six Months
Ended
June 30, 2018
                 
Interest expense   $ 1,085,371     $ —       $ 1,085,371     $ —    
Product development     1,047,981       537       1,048,318       185,404  
Professional     193,485       189,968       392,677       401,151  
General, selling and administration     541,209       107       805,865       977,576  
                                 
    $ 2,868,046     $ 190,612     $ 3,332,231     $ 1,564,131  

 

  16  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

 

7.        Additional Paid-in Capital (continued)

 

Stock options (continued)

 

The Company uses the fair value method for determining stock-based compensation for all options granted during the fiscal periods. The fair value was determined using the Black-Scholes option pricing model based on the following weighted average assumptions:

 

    June 30,
2019
  December 31,
2018
         
Risk-free interest rate     2.06 %     2.52 %
Expected life     5 Years       5 years  
Expected dividends     0 %     0 %
Expected volatility     316 %     309 %
Forfeiture rate     0 %     0 %

 

The weighted average fair value for the options granted during the six months ended June 30, 2019 was $0.04 (December 31, 2018 - $0.06).

 

 

8.         Related Party Transactions and Balances

 

    Three months ended
June 30, 2019
  Three months ended
June 30, 2018
  Six months
ended
June 30, 2019
  Six months
ended
June 30, 2018
      $       $       $       $  
Related party transaction included within interest expense:                                
Interest expenses on promissory notes issued to relatives of the Chairman & Chief Executive Officer of the Company     74,780       74,782       149,562       149,562  
Interest expense on lines of credit payable to the Chairman & Chief Executive Officer of the Company and his spouse     338,895       319,872       672,145       634,506  
Interest expense related to the modification of stock options held by the Chairman and Chief Executive Officer of the Company and his spouse related to financing provided     1,085,371       —         1,085,371       —    
 Related party transactions including within selling, general and administration expenses:                                
Consulting fees to the Chairman & Chief Executive Officer of the Company accrued on the line of credit available to the Company     47,400       47,400       94,800       94,800  
Stock options granted to four members of the Board of Directors of the Company     505,832       —         770,421       —    
Selling, general and administration expense related to the modification of stock options to three members of the Board of Directors     799,625       —         799,625       —    

 

  17  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

8.         Related Party Transactions and Balances (continued)

 

Interest on promissory notes payable to related parties, management compensation and compensation paid to a relative of a director have been recorded at the exchange amount, which is the amount agreed to by the parties. Options granted to related parties have been recorded at their estimated fair value.

 

 

9.         Commitments and Contingencies

 

a) Contingencies

 

The Company has had three judgments against it relating to overdue promissory notes and accrued interest and a fourth creditor has demanded repayment of an overdue promissory note and accrued interest. To date, the Company has not repaid any of these promissory notes and related accrued interest and could be subject to further action. The legal liability, totaling $1,170,168 (December 31, 2018 - $1,113,768), of these promissory notes and related accrued interest have been fully recognized and recorded by the Company. The Company has accrued interest of $208,472 (December 31, 2018 - $196,472) related to one of these promissory notes.

 

b) Commitments

 

i) The Company has a consulting arrangement with Sidney Chan, Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the contract, Mr. Chan will be paid $180,000 per annum for services as Chief Executive Officer. The contract can be terminated at any time with thirty days’ notice and the payment of two years’ annual salary. Should the contract be terminated, all debts owed to Mr. Chan and his spouse must be immediately repaid. The initial term of the contract is for one year and automatically renews for continuous one-year terms. Also, under the terms of the contract are the following:

 

(1) Incentive revenue bonus

 

Mr. Chan will be entitled to a 1% net sales commission from the sales of any of the Company’s products at any time during his life, regardless if Mr. Chan is still under contract with the Company.

 

(2) Sale of business

 

If more than 50% of the Company’s stock or assets are sold, Mr. Chan will be compensated for entering into non-compete agreements based on the selling price of the Company or its assets as follows:

 

- 2% of sales price up to $24,999,999 plus;
- 3% of sales price between $25,000,000 and $49,999,999 plus;
- 4% of sales price between $50,000,000 and $199,999,999 plus; and
- 5% of sales price in excess of $200,000,000.

 

  18  

 

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

9.         Commitments and Contingencies (continued)

 

ii) On June 13, 2018, Mr. Sidney Chan, Chief Executive Officer and Chairman of the Board of Directors of the Company accepted a proposal from the Board of Directors of the Company to purchase the $5,000,000 convertible debenture financing (the “Financing”). The Note will be convertible for a period of 5 years, will bear interest at a rate of 8% per annum and will be repayable in four equal semi-annual instalments starting 42 months after its issuance until maturity. The Note will be transferable or saleable by the Chairman or other holder thereof, in whole or in part, at any time without notice to the Company.

 

On September 20, 2018, the parties agreed to increase the proposed Financing from $5,000,000 to $7,000,000. On October 25, 2018, the parties agreed to increase the proposed Financing from $7,000,000 to $8,500,000. On April 18, 2019, the parties agreed to increase the proposed financing from $8,500,000 to $22,000,000. On July 15, 2019, the parties agreed to increase the proposed financing from $22,000,000 to $25,000,000 (the “Amended Financing”) whereby $12,000,000 would be in the form of settling existing debts owed by the Company to the Chairman, $3,000,000 will be available to settle promissory notes and accounts payable and $10,000,000 would be through the advance of cash. The Amended Financing will continue to be convertible into shares of common stock of the Company at $0.05 per share. The Company has reserved up to 500,000,000 shares of common stock with respect to the possible exercise of the Note.

 

The Company and the Chairman are continuing discussions on a definitive agreement to implement the Note with the customary terms, conditions and representations of a commercial lending agreement. The closing of the Amended Financing and sale of the Note will not occur until such time that is 30 days subsequent to the confirmation of the Company’s first commercial sale of its diabetes management software program, which has not yet occurred.

 

10.         Subsequent Event

 

On July 15, 2019, the Company’s Board of Directors approved the grant of options to acquire 27,500,000 shares of common stock as follows:

· the option to acquire 7,500,000 shares of common stock is granted to one individual, is exercisable at $0.035 per share, will vest immediately and will be exercisable until February 3, 2024;
· the option to acquire 10,000,000 shares of common stock will vest subject to the performance conditions listed below, will be exercisable at a price of $0.04 per share and will be exercisable until July 15, 2024; and
· the option to acquire 10,000,000 shares of common stock:
o is allocated towards the formation of a Latin American sales team;
o will be granted upon the recruitment of sales personnel in Latin America;
o will have performance vesting conditions to be determined by the Company’s Board of Directors at grant; and
o will be set for expiration on or before July 15, 2024.

 

  19  

 

ALR TECHNOLOGIES INC.

Notes to Condensed Financial Statements

($ United States)

(Unaudited)

 

10.         Subsequent Event (continued)

 

The option to acquire 10,000,000 shares of common stock referenced above, which will vest subject to performance conditions, is approved for grant as to 5,000,000 options to two prospective Sales Agents of the Company. The options are approved to vest to each Sales Agent upon:

· each agent enrolling a total of 20,000 ALRT Diabetes Management Solution customers in certain countries located in Asia; or
· such other activities that would provide similar business impact in the sole discretion of the Board of Directors of the Company.
  20  

 

 

ITEM 2. MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-Looking Statements

 

The following information must be read in conjunction with the unaudited Financial Statements and Notes thereto included in Item 1 of this Quarterly Report and the audited Financial Statements and Notes thereto and Management Discussion and Analysis or Plan of Operations contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Except for the description of historical facts contained herein, the Form 10-Q contains certain forward-looking statements concerning future applications of the Company’s technologies and the Company’s proposed services and future prospects that involve risk and uncertainties, including the possibility that the Company will: (i) be unable to commercialize services based on its technology, (ii) ever achieve profitable operations, or (iii) not receive additional financing as required to support future operations, as detailed herein and from time to time in the Company’s future filings with the Securities and Exchange Commission (“SEC”) and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are stated in United States dollars and are prepared in accordance with United States generally accepted accounting principles.

 

In this quarterly report, unless otherwise specified, all references to “common shares” refer to the common shares in our capital stock.

 

As used in this quarterly report, the terms “we”, “us”, “our”, the “Company” and “ALRT” mean ALR Technologies Inc., unless otherwise indicated.

 

Overview

 

ALR TECHNOLOGIES INC. (the “Company” or “ALRT”) was incorporated under the laws of the State of Nevada on March 24, 1987 as Mo Betta Corp. In April 1998, the Company changed its business purpose to marketing a pharmaceutical compliance device.

 

On October 21, 1998, the Company entered into an agreement with A Little Reminder Inc. (“ALR”) whereby the Company would have the non-exclusive right to distribute certain products of ALR described below.

 

In December 1998, the common shares of the Company began trading on the Bulletin Board operated by the National Association of Securities Dealers Inc. under the symbol “MBET”. On December 28, 1998, the Company changed its name from Mo Betta Corp. to ALR Technologies Inc. Subsequently the symbol was changed to “ALRT”.

 

In April 1999, the Company acquired 99.9% (36,533,130) of the issued and outstanding Class A shares of common stock of ALR in exchange for 36,533,130 shares of the Company’s common stock thereby making ALR a subsidiary corporation of the Company. ALR also had outstanding 124,695 shares of Class B common stock, none of which was owned by the Company.

 

ALR was incorporated pursuant to the Company Act of British Columbia on May 24, 1996. ALR owned one subsidiary corporation, Timely Devices, Inc. (“TDI”). TDI was founded in Edmonton, Alberta, Canada, on July 27, 1994. ALR owned all of the total outstanding shares of TDI. TDI had only one class of common stock outstanding.

 

On July 31, 2000, the Company sold all of its shares of ALR. From that point onward, the Company focused on developing its own technology, products and performed its own marketing.

  21  

 

 

On April 15, 2008, the Company incorporated a wholly owned subsidiary in Canada under the name Canada ALRTech Health Systems Inc. This subsidiary was wound up during 2017.

 

In late 2011, the Company relocated its headquarters to 7400 Beaufont Springs Drive, Suite 300, Richmond, Virginia, 23225.

 

During 2011, the Company received FDA clearance and achieved HIPPA compliance for its Diabetes Management System. With these key achievements and successful clinical trials completed, the Company began implementing its commercialization strategy that included a pilot program with patients in Kansas in 2014. The Company obtained significant findings from this pilot program, which led to the development of its Insulin Dosage Adjustment (“IDA”).

 

During 2017, the Company received FDA clearance for IDA and submitted worldwide patent application under the patent cooperation treaty to the World Intellectual Property Organization for its Predictive A1c innovation. The Company is actively seeking to commence revenue-generating activities for its Diabetes Management System.

 

Recent Developments

 

On January 31, 2018, the Company’s Board of Directors approved the following grants:

· the option to acquire 47,000,000 shares of common stock of the Company at a price of $0.015 per share for a term of five years to nine consultants and advisors of the Company; and
· the option to acquire 200,000 shares of common stock of the Company at a price of $0.03 per share until April 18, 2019 to one consultant of the Company.

 

Of the options granted with a term of five years, options to acquire a total of 11,000,000 shares of common stock were granted to three relatives of the Chairman of the Board.

 

On June 3, 2018, the Company received notification that an option holder would be exercising their option to acquire 1,000,000 shares of common stock of the Company at a price of $0.015 by extinguishing $15,000 of accounts payable owed by the Company to the option holder . The options were exercised and shares issued on June 19, 2019 subsequent to the options being fully vested.

 

On June 13, 2018, the Company announced that its Board of Directors have elected to migrate or re-domicile the Company from the United States of America to Canada (the “Migration”). Accordingly, the Board has instructed Management to work with legal counsel to present a suitable Migration plan for the Company that is in compliance with all applicable regulatory authorities.

 

On June 13, 2018, the Company granted a consultant the option to acquire a total of 5,000,000 shares of common stock of the Company at a price of $0.015 per share for a term of five years. The fair value of the options granted totaled $189,968.

 

On October 1, 2018, the Company’s Board of Directors approved the grant of the option to acquire 300,000 shares of common stock of the Company at a price of $0.05 per share for a term of five years to one consultant.

 

On April 12, 2019, the Company’s Board of Directors approved the modification of the option to purchase an aggregate 564,350,200 shares of common stock of the Company to extend the maturity date to April 12, 2024. The option to acquire 564,350,200 shares of common stock was held by 13 individuals, including 560,000,200 held by the Chairman and Chief Executive Officer (or the “Chairman”) and 2,000,000 held by three non-executive directors.

 

On May 6, 2019, the Company’s Board of Directors approved the grant of stock options to purchase 13,000,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to three non-executive directors of the Company.

 

On May 17, 2019, the Company’s Board of Directors approved the grant of option to acquire 27,900,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to 13 optionees and 40,000,000 shares of common stock of the Company at a price of $0.050 for a term of five years to 3 optionees as follows:

 

Number of

Optionees

Position Option to acquire common stock
Three (3) Sales Agent 40,000,000
One (1) Non-executive Member of the Board of Directors 1,000,000
Seven (7) Software Development Team Member 19,700,000
One (1) Manager, Procurement and Quality Assurance 3,000,000
Four (4) Clinical Team Member 4,200,000

 

  22  

 

The option to acquire 40,000,000 shares of common stock approved for grant to Sales Agents will vest when the three Sales Agents (the “US Sales Team”) sign up a total of 20,000 ALRT Diabetes Management Solution customers in the United States of America prior to May 30, 2020 (the “Sales Target”).

 

On June 17, 2019, the Company’s Board of Directors approved the grant of the option to acquire 15,000,000 shares of common stock of the Company at a price of $0.035 per share for a term of five years to three optionees as follows:

 

Number of

Optionees

Position Option to acquire common stock
Two (2) Sales Agent 10,000,000
One (1) Advisor 5,000,000

 

The option to acquire 10,000,000 shares of common stock approved for grant to Sales Agents were granted as 5,000,000 options to each Sales Agent. The 5,000,000 options to each Sales Agents will vest when each Sales Agent signs up 20,000 Diabetes Management Solution customers in the United States of America prior to August 31, 2020 (the “Sales Target”). To date, only 10,000,000 of the Option Shares have been granted while the Company remains in discussion with engagement of a Sales Agent for the remaining 5,000,000.

 

On June 19, 2019, the Chairman of the Company exercised the option to acquire 25,000,000 shares of common stock at a price of $0.002 per share for a total purchase price of $50,000. The Chairman extinguished an outstanding debt owed by the Company to him in the amount of $50,000 as consideration. The Company also issued 1,000,000 common shares for the exercise of options a price of $0.015 per share for a total purchase price of $15,000 which was settled with the extinguishment of accounts payable.

 

On July 15, 2019, the Company’s Board of Directors approved the grant of the option to acquire 27,500,000 shares of common stock. Of the options approved for grant:

· the option to acquire 7,500,000 shares of common stock is granted to one individual, is exercisable at $0.035 per share, will vest immediately and will be exercisable until February 3, 2024;
· the option to acquire 10,000,000 shares of common stock will vest subject to the performance conditions listed below, will be exercisable at a price of $0.04 per share and will be exercisable until July 15, 2024; and
· the option to acquire 10,000,000 shares of common stock:
o is allocated towards the formation of a Latin American sales team;
o will be granted upon the recruitment of sales personnel in Latin America;
o will have performance vesting conditions to be determined by the Company’s Board of Directors at grant; and
o will be set for expiration on or before July 15, 2024.

 

The option to acquire 10,000,000 shares of common stock referenced above, which will vest subject to performance conditions, is approved for grant as to 5,000,000 options to two prospective Sales Agents of the Company. The options are approved to vest to each Sales Agent upon:

· each agent enrolling a total of 20,000 ALRT Diabetes Management Solution customers in certain countries located in Asia; or
· such other activities that would provide similar business impact in the sole discretion of the Board of Directors of the Company.

 

Financing

 

On September 25, 2017, the Company announced that it had authorized a private placement up to $5 million for the issuance of convertible debentures that are convertible into shares of common stock of the Company at a price of $0.05 per share (the “Note”).

 

On June 13, 2018, the Chairman and Chief Executive Officer of the Company accepted a proposal from the Board of Directors of the Company to purchase the $5,000,000 convertible debenture financing (the “Financing”). The Note will be convertible for a period of 5 years, will bear interest at a rate of 8 per cent per annum and will be repayable in four equal semi-annual instalments commencing 42 months after its issuance until maturity. The Note will be transferable or saleable by the Chairman or other holder thereof, in whole or in part, at any time without notice to the Company.

 

On September 20, 2018, the parties agreed to increase the proposed Financing from $5,000,000 to $7,000,000. On October 25, 2018, the parties agreed to increase the proposed Financing from $7,000,000 to $8,500,000. On April 18, 2019, the parties agreed to increase the proposed financing from $8,500,000 to $22,000,000. The July 15, 2019, the parties agreed to increase the proposed financing from $22,000,000 to $25,000,000 (the “Amended Financing”) whereby $12,000,000 would be in the form of settling existing debts owed by the Company to the Chairman, $3,000,000 would be available to settle promissory notes payable and accounts payable and $10,000,000 would be through the advance of cash. The Amended Financing will continue to be convertible into shares of common stock of the Company at $0.05 per share. The Company has reserved up to 500,000,000 shares of common stock with respect to the possible exercise of the Note.

 

The Company and the Chairman are continuing discussions on a definitive agreement to implement the Note with the customary terms, conditions and representations of a commercial lending agreement. The closing of the Amended Financing and sale of the Note will not occur until such time that is 30 days subsequent to the confirmation of the Company’s first commercial sale of its diabetes management software program which has not yet occurred.

 

Products

 

ALR Technologies products utilize internet-based technologies to facilitate a healthcare provider’s ability to monitor their patient’s health and ensure adherence to health maintenance activities.

 

  23  

 

The ALRT Diabetes Management System is a remote monitoring and care facilitation program that allows patients to upload the blood glucose data from their glucometers. ALRT Health Data Monitors monitor that data and, based on clinician approved protocols, provide advice, support and interventions when patients show blood glucose readings that are out of an acceptable range or if they are failing to test their blood glucose as prescribed. The ALRT System has been successfully proven in a clinical trial that demonstrated this type of remote care is associated with significant lowering of A1c levels. The study concluded that continuing intervention using an internet-based glucose monitoring system is an effective way of improving glucose control compared to conventional care. A second clinical trial demonstrated that this type of Internet-based Blood Glucose Monitoring System (IBGMS) was associated with comparable reductions in A1c levels with that of more expensive Continuing Glucose Monitoring Systems (CGMS).

 

In the future, the Company may seek to adapt its System to be used in the management of other chronic diseases. The Company may be required to obtain additional clearance from the FDA prior to commencing selling activities in the United States for other disease states.

 

ALRT Diabetes Management System

 

Diabetes is a leading cause of death, serious illness and disability across North America. In the United States, it is estimated that 26 million people have diabetes, with 4.5 million people being classified as insulin dependent. By the year 2030, it is expected that 1 in 10 adults, globally, will have diabetes (diagnosed and undiagnosed instances). By the year 2050, it is expected that 1 in 3 United States adults will have diabetes (diagnosed and undiagnosed instances). We believe diabetes is a global pandemic.

 

As a result, medical costs due to diabetes and its complications are enormous. In the United States, such costs are estimated to be over $245 billion a year. In Canada, where it is estimated there are 2 million people with diabetes, healthcare costs associated with diabetes is estimated to be more than $13 billion annually.

 

Diabetes is a lifelong chronic disease with no cure. However, people with diabetes can take steps to control their disease and reduce the risk of developing the associated serious complications, thereby controlling healthcare costs. The Canadian Diabetes Association Clinical Practice Guidelines Expert Committee reports that, “Successful diabetes care depends on the daily commitment of persons with diabetes mellitus to self-manage through the balance of lifestyle and medication. Diabetes care should be organized around a multi- and interdisciplinary diabetes healthcare team that can establish and sustain a communication network between the person with diabetes and the necessary healthcare and community systems”.

 

However, as noted in Patrick Connole, “UnitedHealthcare, Other Large Insurers Seek Better Adherence to Diabetes Care”, Health Plan Week, February 11, 2013 Volume 23 Issue 5, 80% of United States patients with diabetes do not follow their prescribed care plan.

 

 

  24  

 

ALRT Diabetes Management System (continued)

 

Furthermore, in Treatment intensification for patients with type 2 diabetes and poor glycaemic control by Fu and Sheenan, it was noted that out of 11,525 patients investigated with an A1c greater than 8% patients received intensification as follows:

  • 37% within 6 months;
  • 11% within 6-12 months; and
  • 52% never.

 

A study in 2013 by Khunti, Wolden, Thorstead, Anderson and Davies entitled Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people found that it took on average 19 months to escalate patients with an average A1c of 8.7% from single medication to dual therapy and 82 months to escalate patients with an average A1c of 8.8% from dual medication to triple therapy. Furthermore, they found that it took approximately 20 years to advance patients with an average A1c of over 9% to insulin. At the end of the study, less than 50% of the patients had their treatment intensified.

 

The Company’s Diabetes Management System provides an affordable and easy to use tool to provide the communication network as recommended by the Committee. Our Diabetes Management System includes a communications software platform that also enables health professionals to remotely monitor the health progress to patients with diabetes. This facilitates more timely and effective communication and coordination of care to these patients. This also results in positive behavior patterning, or re-patterning, of the patients.

 

The Diabetes Management System and the Company’s universal upload cable, are compatible with the majority of the major brands of glucose meters available for sale in the United States.

 

In August 2010, the Company received the results of a clinical trial conducted by Dr. Hugh Tildesley using the ALRT Health-e-Connect System. The trial showed A1c dropping from 8.8% to 7.6% for the Intervention Group using ALRT’s Health-e-Connect System as part of a diabetes management program. The A1c test is important in diabetes treatment management as a long-term measure of control over blood glucose for diabetes patients. According to the Center for Disease Control and Prevention, “In general, every percentage drop in A1c blood test results (e.g., from 8% to 7%), can reduce the risk of microvascular complications (eye, kidney and nerve diseases) by 40%”. The trial served as the basis for an article titled Effect of Internet Therapeutic Intervention on A1c Levels in Patients with Type 2 Diabetes Treated with Insulin , which was published in the August 2010 Diabetes Care publication.

 

In July 2011, the follow-up results of the Dr. Tildesley clinical trial were published in the Canadian Journal of Diabetes . Dr. Tildesley conducted a 12-month study using Health-e-Connect System as an Internet-Based Blood Glucose Monitoring System (IBGMS) to provide intensive blood glucose control to determine the effects of internet-based blood glucose monitoring on A1c levels in patients with type 2 diabetes treated with insulin. Dr Tildesley concluded that, “While IBGMS intervention was not a substitute for the patient–physician interaction in a clinical setting, it significantly improved A1c and, over time, we observed better glycaemic control and patient satisfaction”.

 

In October 2011, the Company received 510(k) clearance from the US Food and Drug Administration (FDA) for its Diabetes Management System (then known as the Health-e-Connect System) for remote monitoring of patients in support of effective diabetes management programs. The 510(k) clearance enables the Company to commence with the United States marketing and sales launch of its Health-e-Connect System.

 

  25  

 

ALRT Diabetes Management System (continued)

 

On July 28, 2014, the Company entered into a pilot service agreement with Kansas City Metropolitan Physician Association (KCMPA), one of the nation's premier Accountable Care Organizations (ACO). Under the agreement, KCMPA, which made diabetes management a key focus of its Quality Improvement Plan, enrolled up to 200 of its patients with Type 2 diabetes into ALRT's Diabetes Management System. The pilot service agreement was effective nine months from the beginning date of patient enrollment and the intent was to allow 6 months of use for each patient enrolled in the system. The pilot program between ALRT and KCMPA represented the first commercial deployment of ALRT's Diabetes Management System. On September 9, 2014, the Company began enrolling patients with Type 2 diabetes and A1c levels above 8 percent into the pilot program trialing the Diabetes Management System.

 

In September 2014, the Company initiated its pilot program with one of the Kansas City Metropolitan Physician Association clinics to deploy its Diabetes Management System for up to 200 patients that fit certain criteria. As a result of the pilot program findings and general industry trends, the Company proceeded with developing three new innovations:

· Insulin Dosage Adjustment uses both American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) guidelines for adjusting insulin;
· Predictive A1c, which converts blood glucose data uploaded into our Diabetes Management Systems and converts the large amount of data into a predicted or simulated A1c; and
· Diabetes Therapy Review allows the healthcare providers to change care plans for patients on a timely basis based on the results of Predictive A1c and overall how patients are managing their diabetes.

 

On January 1, 2015, the Center for Medicaid and Medicare Services began reimbursing physicians for the non-face-to-face management of Medicare patients with two or more serious chronic diseases. Physicians would be paid a per-patient-per-month fee for “Chronic Care Management” and the examination of data from a remote monitoring platform is considered a reimbursable activity by CMS. Therefore, the Company modified its System to conform to the requirements of the CMS reimbursement. These modifications permit the Company to market to medical groups throughout the United States with a product that will help physicians to draw down this new reimbursement, as well as to potentially improve the outcomes of their patients.

 

On February 18, 2015, the Company filed a 510(k) application with the FDA to add a remote insulin dosing recommendation feature to the Company’s Diabetes Management System. The Company utilized the publicly available algorithm of the AACE and ADA. This feature allows the Company to regularly run a patient’s blood glucose data (and other key data) through the AACE and ADA algorithm. When the algorithm indicated that the patient’s dose may not be optimal, the Diabetes Management System would provide the healthcare provider that a dose change may be warranted and what the change would be based on AACE and ADA guidelines. The decision about the dose change would rest entirely with the healthcare provider. However, this new feature may make a significant contribution to improving the outcomes of diabetes patients if it allowed healthcare providers to keep their patients at the optimal dose for longer periods.

 

Preliminary data from the KCMPA pilot program indicated that a number of patients had achieved reductions in their A1c levels. On April 17, 2015, the Company signed a commercial contract with one of the KCMPA clinics, the Clay-Platte Family Medicine Clinic, to provide remote monitoring services. The Company has provided these services to date to Clay-Platte at no charge, as it has provided the Company with continuous users as a sample population for its own strategic planning and business plan. The Company continues to actively provide services to Clay-Platte for certain of its patients.

 

On June 20, 2017, the Company filed a worldwide patent application under the PCT for its Predictive A1c feature to the World Intellectual Property Office.

 

On September 18, 2017, the Company received clearance from the FDA for its Insulin Dosage Adjustment feature within the Company’s Diabetes Management System.

  26  

 

Critical Accounting Policies and Going Concern

 

Our discussion and analysis of our results of operations and liquidity and capital resources are based on our unaudited condensed financial statements for the six months ended June 30, 2019 and 2018, which have been prepared in accordance with GAAP.

 

The preparation of these condensed financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. We base our estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results may materially differ from our estimates.

 

The Company’s condensed financial statements have been prepared on a going concern basis, which presumes the realization of assets and the discharge of liabilities and commitments in the normal course of operations for the foreseeable future. See note 1 of the condensed financial statements.

 

Due to our being a development stage company and not having generated significant revenues, in the notes to our financial statements, we have included disclosure regarding concerns about our ability to continue as a going concern.

 

Results of Operations

 

   

Six Months  

Ended 

June 30

   
   
            Amount (%)   Amount ($)
  2019   2018 Increase /   Increase /
            (Decrease)   (Decrease)
Operating Expenses                
General, selling and administrative $ 986,683   $ 1,155,747 (15)   (169,064)
Product development   1,217,901     295,798 312   922,103
Professional fees   437,234     422,135 4   15,099
Total Operating Expenses   2,641,818     1,873,680 41   768,138
                 
Other Item                
Interest expense   2,082,829     959,263 117   1,123,566
Net Loss $ 4,724,647   $ 2,832,943 67   1,891,704

 

The net loss for the Company’s six-month period ended June 30, 2019 was significantly impacted by the grant of options to incentivize personnel as follows as compared to the same period on the previous year:

 

  Six Months Ended June 30, 2019 Six Months Ended June 30, 2018
Options Granted as Compensation 112,550,000 52,200,000
Value of Options Granted as Consideration $0.04 $0.06
Options Modified 564,350,200 -
Compensation expense from Options Granted or Options Modified as a percentage of Net Loss for the Period 71% 54%

 

  27  

 

Results of Operations (continued)

 

The net loss for the six months ended June 30, 2019 was 67% ($1,891,704) higher than the net loss at June 30, 2018 as a result of the grant of options with a fair value recognized of $2,181,171 as consideration for services received and the modification of options resulting in compensation expense of $1,150,060. The fair value from the grant and the modification of the options in the six months ended June 30, 2019 accounted for 115% of the total change in net loss as compared to 2018. Of the 112,550,000 options to acquire shares of common stock granted, 55,000,000 (a fair value of approximately $2.2M) did not vest (and were not recorded) during the period.

 

General, selling and administrative expenses. General, selling and administrative costs consist of salaries and consulting fees of management personnel, stock-based compensation for options granted to management personnel, travel and trade show costs, rent of the Company’s corporate office, website costs, information technology costs and general costs incurred through day-to-day operations. From the six-month period ended June 30, 2019 as compared to the six-month period ended June 30, 2018, there was both a significant decrease and variance in the total expense incurred related primarily to the grant of stock options. By type of general and administrative cost, the variance can be seen as follows:

 

    Six Months Ended
June 30,
  Six Months Ended
June 30,
  Amount ($)
Increase /
(Decrease)
    2019   2018    
             
General, selling and administrative:                        
Salaries and consulting fees   $ 113,000       128,000       (15,000 )
Stock-based compensation     806,000       978,000       (172,000 )
Travel and trade shows     28,000       21,000       7,000  
Rent of corporate offices     1,000       —         1,000  
Website and information technology     8,000       8,000       —    
Other general and administrative costs     31,000       21,000       10,000  
Total   $ 987,000       1,156,000       (169,000 )

 

During the six-month period ended June 30, 2019, aside from the grant of stock options, the Company slightly increased its general and administrative operating expenditures as compared to the same period in 2018. The cash-based general and administrative expenditure increased by approximately $3,000 during the six-month period ended 2019 as compared to 2018.

 

Product development costs. Substantially all of the product development costs incurred related to a) services provided by contractors of the Company, b) expenses incurred for product development, and c) stock-based compensation for options granted to members of the product development team. The change in balance from the previous year relates primarily to an increase in external consulting services related to the grant of stock options to development personnel.

 

Professional fees. Professional costs incurred consist of consulting and advisory fees of certain professionals retained, audit fees, legal fees, diabetes care facilitators and stock-based compensation for options granted to professionals. During the period, there was a increase in professional fees. By type of professional cost, the variance can be seen as follows:

 

    Six Months Ended
June 30,
2019
  Six Months Ended
June 30,
2018
  Amount ($)
Increase /
(Decrease)
             
             
Professional fees:                        
Professionals retained   $ 35,000       13,000       22,000  
Legal fees     9,000       8,000       1,000  
Stock-based compensation     393,000       401,000       (8,000 )
Total   $ 437,000       422,000       15,000  

 

  28  

 

Results of Operations (continued)

 

The increase in professional fees can be attributed to the Company having realized reduced costs of professionals retained due to foreign exchange benefits in the previous year.

 

Interest expense. Interest expense was from the following sources for the six-month periods ended June 30, 2019 and 2018:

 

    Six Months Ended
June 30,
2019
  Six Months Ended
June 30,
2018
Interest expense                
Interest expense incurred on stock options modified   $ 1,085,000     $ —    
Interest expense incurred on lines of credit     672,000       635,000  
Interest expense incurred on promissory notes     264,000       264,000  
Imputed interest on zero interest loans     61,000       60,000  
Total   $ 2,082,000     $ 959,000  

 

Interest Expense on Stock Options Modified

On April 12, 2019, the Company and the Chief Executive Officer of the Company and his spouse agreed to amend the option to acquire 560,000,200 shares of common stock of the Company by extending the life of the option to April 12, 2024. The Company compared the fair values of the option, using the Black-Scholes option pricing model, immediately prior to the grant and immediately after the grant. The Company recognized the incremental fair value totaling $1,085,371 as interest expense related to extending of the life of the option. The interest expense recognized related to the option modification was fully recognized at the time of the modification since the line of credit is due on demand and has no other terms of repayment.

 

Interest on Promissory Notes

There were no substantial changes in the number of promissory notes outstanding from June 30, 2018 to June 30, 2019. During the previous year, the Company transferred amounts from imputed interest to interest on promissory notes and continued recording interest on the outstanding principal during the current period. Related to its promissory notes outstanding, the Company anticipates interest expense to be consistent with the results for the six months ended June 30, 2019 moving forward.

 

Interest on Lines of Credit

The Company has two line of credit facilities that had balances as follows:

 

    June 30,
2019
  June 30,
2018
  Amount ($)
Increase /
(Decrease)
Lines of Credit:            
             
Line of credit provided by Sidney Chan   $ 9,371,000     $ 8,729,000     $ 642,000  
Line of credit provided by Christine Kan     2,000,000       2,000,000       —    
Total   $ 11,371,000     $ 10,729,000     $ 642,000  
                         

 

Results of Operations (continued)

 

The Company incurred interest on the lines of credit as follows:

 

Interest Expense on Lines of Credit:   Six Months   Six Months   Amount ($)  
 

Ended

June 30,

 

Ended

June 30,

 

Increase /

(Decrease)

 
  2019   2018      
               
Interest expense incurred on line of credit from Sidney Chan during the year $ 552,000 $ 514,000

 

$

38,000  
Interest expense incurred on line of credit from Christine Kan during the year   120,000   120,000   -  
Total $ 672,000 $ 634,000 $ 38,000  

 

Imputed Interest

During the 2019 and 2018 periods, the Company had certain zero interest promissory notes and accounts payable in excess of one year. Pursuant to the Company’s accounting policy, these zero interest amounts are considered to be financing items in nature and are assigned a deemed interest rate (1% per month). The interest incurred on these is expensed as imputed interest and, instead of increasing the liabilities of the Company, it is allocated to equity under the financial statement line item Additional paid-in capital. The change from the prior year is related to the discussion included under Interest on Promissory Notes above.

 

  29  

 

Results of Operations (continued)

 

   

Three Months  

Ended 

June 30

   
   
            Amount (%)     Amount ($)
    2019     2018 Increase /     Increase /
            (Decrease)     (Decrease)
Operating Expenses                  
General, selling and administrative $ 641,942   $ 95,160 575   $ 546,782
Product development   1,162,879     55,164 2,008     1,107,715
Professional fees   208,957     199,260 5     9,697
Total Operating Expenses   2,013,778     349,584 476     1,664,194
                   
Other Item                  
Interest expense   1,586,936     482,522 229     1,104,414
Net Loss $ 3,600,714   $ 832,106 333   $ 2,768,608

 

The net loss for the three months ended June 30, 2019 increased by 333% ($2,768,608) as compared to the same period in the prior year as a result of the grant of an option to acquire shares of common stock of the Company with a fair value of $1,718,390. The fair value of the options granted in 2019 accounted for 62% of the increase in net loss from the prior period.

 

Liquidity and Capital Resources

 

Working Capital
 

As at

June 30,

2019

As at

December 31,

2018

 

Amount ($)

Increase / (Decrease)

Percentage (%)

Increase / (Decrease)

Current Assets $ 4,000 $ 3,000   1,000 33
Current Liabilities $ 29,666,000 $ 28,398,000   1,268,000 4
Working Capital Deficiency $ (29,662,000) $ (28,395,000)   (1,267,000) 4

 

The Company has a severe working capital deficiency. It does not have the ability to service its current liabilities for the next twelve months and is reliant on its line of credit facilities to meet its ongoing operations. Until the Company has revenue-producing activities that exceed its operating requirements, it will be unable to service its current liabilities and the working capital deficit will continue to increase. As of the date of this MD&A, the Company has not commenced revenue-generating activities, nor does it know when they will commence. There is substantial doubt about the Company’s ability to repay its current liabilities in the near term or any time in the future, which could ultimately lead to business failure.

 

Current Assets

 

The Company’s nominal current assets as at June 30, 2019 and December 31, 2018 consist substantially of cash.

 

  30  

 

Current Liabilities

 

The Company has current liabilities of $29,665,000 as at June 30, 2019 as compared to $28,398,000 as at December 31, 2018. Current liabilities were as follows:

 

    June 30,
2019
  December 31,
2018
  Change
$
  Change
%
Accounts payable and accrued liabilities   $ 1,048,000       1,014,000       34,000       3  
Promissory notes payable to related parties     2,892,000       2,892,000       —         —    
Promissory notes payable to unrelated parties     2,394,000       2,394,000       —         —    
Interest payable     5,100,000       4,836,000       264,000       5  
Lines of credit to related parties     18,231,000       17,262,000       969,000       6  
Total current liabilities   $ 29,665,000       28,398,000       1,267,000       4  

 

The increase in interest payable of $264,000 relates to accrued interest incurred on promissory notes at their stated rates of interest. All of the promissory notes and related interest payable are overdue.

 

The fluctuations in accounts payable occurred as part of operations.

 

The increase in the lines of credit payable of approximately $969,000 is attributable to borrowings of:

· $347,000 to fund operations, product development activities, overhead, and its sales and marketing program;
· $672,000 of accrued interest incurred on the principal of the borrowed amounts; and
· $50,000 of interest applied towards the exercise of the option to acquire 25,000,000 shares of common stock at a price of $0.002 per share.

 

Cash Flows        
    Six Months Ended   Six Months Ended
    June 30, 2019   June 30, 2018
Cash Flows used in Operating Activities   $ (346,000 )   $ (333,000 )
Cash Flows provided by Financing Activities     347,000       330,000  
Net change in Cash During Period   $ 1,000     $ (3,000 )

 

Cash Balances and Working Capital

 

As of June 30, 2019, the Company’s cash balance was $3,723 compared to $3,378 as of December 31, 2018.

 

Cash Used in Operating Activities

 

Cash used by the Company in operating activities during the six months ended June 30, 2019 was $346,000 in comparison with $333,000 used during the same period last year. The Company’s expenditures from operations were used as follows (approximate amounts):

 

    Six Months Ended
June 30, 2019
  Six Months Ended
June 30, 2018
         
Product development consulting and expenses   $ 117,000     $ 108,000  
Management and employees’ compensation     113,000       128,000  
Professional fees and related accounts payable     66,000       63,000  
Travel and trade shows     28,000       20,000  
Other     22,000       14,000  
Cash used in Operations   $ 346,000     $ 333,000  

 

The majority of the expenditures were to repay overdue accounts payable owing to certain consultants, pay product development costs, pay accrued professional fees, and selling and administration costs associated with operating the business.

 

Cash Proceeds from Financing Activities

 

Cash sourced by the Company from financing activities during the six-month period ended June 30, 2019 was $347,000 in comparison with $330,000 sourced during the same period last year. The funds sourced from lines of credit provided by Chairman of the Board and a relative of the Chairman of the Board. The loans received in 2019 and 2018 covered the operating, product development and market development requirements for the Company to repay certain accounts payable.

  31  

 

 

Short- and Long-Term Liquidity

 

As of June 30, 2019, the Company does not have the current financial resources and committed financing to enable it to meet its administrative overhead, product development budgeted costs and debt obligations over the next 12 months.

 

All of the Company’s debt financing is due on demand or overdue. The Company will seek to obtain creditors’ consents to delay repayment of these loans until it is able to replace these financings with funds generated by operations, replacement debt or from equity financings through private placements, or the exercise of options and warrants. While the Company’s creditors have agreed to extend repayment deadlines in the past, there is no assurance that they will continue to do so in the future. The Company has faced litigation from creditors in the past and is currently being sued by one creditor. There is no assurance that additional creditors will not make claims against the Company in the future. Failure to obtain either replacement financing or creditor consent to delay the repayment of existing financing could result in the Company having to curtail operations.

 

Tabular Disclosure of Contractual Obligations:

 

    Payments due by period
              Less than       1-3       3-5       More Than  
      Total       1 year       years       years       5 Years  
                                         
Accounts payable and accrued liabilities   $ 1,048,000     $ 1,048,000     $ —       $ —       $ —    
Promissory notes to related parties     2,892,000       2,892,000       —         —         —    
Promissory notes to arm’s length parties     2,394,000       2,394,000       —         —         —    
Interest payable     5,100,000       5,100,000       —         —         —    
Lines of credit from related parties     18,231,000       18,231,000       —         —         —    
    $ 29,665,000     $ 29,665,000     $ —       $ —       $ —    

 

The Company will continue to use the funds available from the lines of credit to cover administrative overhead and product development requirements until such time it can establish cash flows from operations. In the next six months, the Company anticipates the amount borrowed from the lines of credit to increase as compared to the past six months, as it expects to commercially launch its Diabetes Management System during this period.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet financing arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, that is material to investors.

 

  32  

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.

 

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Under the supervision and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based on this assessment, we found our internal and disclosure controls over financial reporting to be not effective for the following reasons:

 

1) insufficient written policies and procedures for reporting requirements and accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.

 

While the Company is working to remedy these deficiencies as its business activities evolve, there were no changes in our internal or disclosure controls over financial reporting during the quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

There were no other changes from the period beginning April 1, 2019 to the date of this 10Q.

 

ITEM 1A. RISK FACTORS.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

As at June 30, 2019, the Company had promissory notes payable and related interest payable, totalling $10,387,000 in default.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

  33  

 

ITEM 6. EXHIBITS.

 

Exhibit   Incorporated by reference Filed
No. Document Description Form Date Number herewith
3.1 Initial Articles of Incorporation. 10-SB 12/10/99 3.1  
3.2 Bylaws. 10-SB 12/10/99 3.2  
3.3 Articles of Amendment to the Articles of Incorporation, dated October 22, 1998. 10-SB 12/10/99 3.3  
3.4 Articles of Amendment to the Articles of Incorporation, dated December 7, 1998. 10-SB 12/10/99 3.4  
3.5 Articles of Amendment to the Articles of Incorporation, dated January 6, 2005. 8-K 1/20/05 3.1  
3.6 Amendment to Bylaws, dated October 13, 2011 8-K 10/17/11    
3.7 Amendment to Bylaws, dated April 10, 2012 8-K 4/16/12    
10.1 Consulting Agreement with Endocrine Research Society Inc. 10-KSB 10/01/13 10.1  
14.1 Code of Ethics. 10-KSB 4/14/03 14.1  
31.1

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

      X
32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

      X
99.01 Distribution Agreement with Mo Betta Corp. 10-SB 12/10/99 99.1  
99.02 Pooling Agreement. 10-SB 12/10/99 99.2  
99.03 Amended Pooling Agreement. 10-SB 12/10/99 99.3  
99.04 Lock-Up Agreement. 10-SB 12/10/99 99.4  
99.19 Audit Committee Charter. 10-KSB 3/31/14 99.19  
99.20 Disclosure Committee Charter. 10-KSB 4/14/03 99.20  
99.30 Nomination Committee Charter 10-KSB 3/31/14 99.30  
99.40 Compensation Committee Charter 10-KSB 3/31/14 99.40  
  34  

 

 

SIGNATURES

 

Pursuant to the requirements of Sections 13 or 15(d) of the Securities and Exchange Act of 1934 , the Registrant has duly caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 14 th day of August 2019.

 

  ALR TECHNOLOGIES, INC.
  (Registrant)
   
  BY: SIDNEY CHAN
    Sidney Chan
    Principal Executive Officer, Principal Accounting Officer, Principal Financial Officer, Secretary/Treasurer and Director

 

 

 

  35  

Alr Technologies, Inc. (PC) (USOTC:ALRT)
Historical Stock Chart

1 Year : From Sep 2018 to Sep 2019

Click Here for more Alr Technologies, Inc. (PC) Charts.

Alr Technologies, Inc. (PC) (USOTC:ALRT)
Intraday Stock Chart

Today : Friday 20 September 2019

Click Here for more Alr Technologies, Inc. (PC) Charts.

Latest ALRT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.